Bagsværd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on 23 March 2017, it was decided to reduce the company's B share capital from DKK 402,512,800 to DKK 392,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 500,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 392,512,800.
The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.
|Anne Margrethe Hauge||+45 3079 email@example.com (mailto:firstname.lastname@example.org)|
|Peter Hugreffe Ankersen||+45 3075 email@example.com (mailto:firstname.lastname@example.org)|
| Hanna Ögren|
Kasper Veje (US)
| +45 3079 8519|
+45 3079 4461
+1 609 235 8567
| email@example.com (mailto:firstname.lastname@example.org)|
Company announcement No 29 / 2017
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire